Risankizumab maintains skin, joint symptom resolution in psoriatic arthritis at 100 weeks
Click Here to Manage Email Alerts
Adult patients with active psoriatic arthritis who received risankizumab reported sustained improvements in skin and joint symptoms at week 100 in two ongoing phase 3 trials, according to data released by AbbVie.
“We’re pleased to share these new, nearly 2-year analyses, which showed Skyrizi maintained improvements across joint and skin measures of psoriatic arthritis over time,” Doina Cosma-Roman, MD, vice president and global head of clinical development for immunology at AbbVie, said in a company release. “It is critically important for physicians to have treatment options that demonstrate lasting efficacy, as we know people living with psoriatic arthritis discontinue therapies due to loss of efficacy or tolerability.”
The data come from the phase 3 KEEPsAKE 1 and 2 trials and were presented as late-breaking content at the European Academy of Dermatology and Venereology Hybrid Congress in Milan. The multicenter, randomized, double-blind, placebo-controlled studies aim to investigate the safety and efficacy of risankizumab (Skyrizi, AbbVie) in patients with psoriatic arthritis.
According to the press release, 64% and 57% of patients who received risankizumab in the KEEPSaKE 1 and 2 trials, respectively, maintained an ACR20 response at 100 weeks. Furthermore, 71% and 67% of treated patients who had body surface area involvement of at least 3% at baseline achieved PASI90, and 76% and 57% of patients achieved resolution of dactylitis and enthesitis.
Risankizumab was mostly well-tolerated, the release stated, with no new reported safety signals in either trial at 100 weeks.
“These results highlight Skyrizi’s potential to relieve symptoms in both biologic-naïve and -experienced patients with active psoriatic arthritis in the long-term,” Lars Erik Kristensen, MD, PhD, a consultant and head of science at the Parker Institute in Copenhagen, Denmark, and associate professor at SUS University Hospital in Lund, Sweden, said in the release.
Read more about
Click Here to Manage Email Alerts